A type of small cell lung cancer marked by the NKX2-1 gene
Lineage evolution of a small cell lung cancer epigenomic subtype signified by NKX2-1
Researchers will look at how the NKX2-1 gene shapes a subtype of small cell lung cancer to help find better treatments for people with this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11240326 on NIH RePORTER |
What this research studies
This work will map epigenetic (gene regulation) patterns in tumors to define an NKX2-1–marked subtype of small cell lung cancer. The team will analyze patient tumor samples alongside lab models and molecular profiling to see how these tumors change over time and with treatment. By comparing patterns across samples, they aim to find specific weaknesses or biomarkers that could point to new treatment strategies.
Who could benefit from this research
Good fit: People with small cell lung cancer who can provide tumor samples or biopsies, especially if their tumor tests positive for NKX2-1, would be the most relevant candidates to participate or contribute samples.
Not a fit: Patients without small cell lung cancer, those whose tumors lack the NKX2-1 marker, or anyone seeking an immediate treatment benefit are unlikely to receive direct clinical benefit from this research.
Why it matters
Potential benefit: If successful, this could point to new targeted treatments or biomarkers that improve treatment choices and outcomes for people with small cell lung cancer.
How similar studies have performed: Previous studies have identified molecular and epigenetic subtypes of lung cancers and have used such profiles to find treatment targets, but focusing on the NKX2-1–marked SCLC subtype is a relatively new approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Watanabe, Hideo — Icahn School of Medicine at Mount Sinai
- Study coordinator: Watanabe, Hideo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.